Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and Leukemia, Myeloid, Acute

quinazolines has been researched along with Leukemia, Myeloid, Acute in 77 studies

Research

Studies (77)

TimeframeStudies, this research(%)All Research%
pre-19903 (3.90)18.7374
1990's0 (0.00)18.2507
2000's26 (33.77)29.6817
2010's43 (55.84)24.3611
2020's5 (6.49)2.80

Authors

AuthorsStudies
Ding, L; Fan, W; Jiao, X; Tang, C; Zhang, Q; Zhao, K; Zhou, Y1
Bai, M; Li, C; Li, M; Li, Y; Liu, H; Lu, S; Ma, S; Su, P; Yin, X; Zhang, C1
Chen, Y; Deng, H; Du, W; Gao, H; He, Q; Lan, T; Li, T; Liu, Y; Meng, X; Rao, Y; Shao, X; Sun, X; Tao, X; Tong, Y; Wang, L; Wang, W; Wu, Y; Xu, A; Yang, B; Ying, M; Zhong, T1
Andreeff, M; Blaukat, A; Carr, MI; Haines, E; Montoya, RH; Nishida, Y; Ostermann, LB; Vassilev, LT; Zenke, FT; Zhang, W1
Azimi, A; Goroshchuk, O; Jafari, R; Kolosenko, I; Kunold, E; Palm-Apergi, C; Pirmoradian, M; Vidarsdottir, L1
Gray, NS; Hellwig, S; Liu, Y; Smithgall, TE; Tan, L; Weir, MC1
Chen, L; Gray, NS; Hellwig, S; Patel, RK; Shu, ST; Smithgall, TE; Tan, L; Weir, MC1
Katayama, K; Noguchi, K; Sugimoto, Y; Takami, M1
Cheung, HK; Coxon, A; Crispino, JD; Hanestad, K; Juan, G; Marinaccio, C; Ninniri, MSS; Payton, M; Wayne, WC1
Achenbach, H; Besses, C; Birgegård, G; Folkvaljon, F; Garmo, H; Griesshammer, M; Gugliotta, L; Harrison, CN; Holmberg, L; Kiladjian, JJ; Wu, J1
Gao, X; Liu, X; Niu, M; Pan, T; Qi, J; Wang, R; Wu, Q; Xu, K; Yao, Y; Zhang, H; Zhang, N; Zhong, X1
Alvarez-Larrán, A; Besses, C; Cervantes, F1
Albanese, C; Alzani, R; Amboldi, N; Bungaro, S; Casolaro, A; Cazzaniga, G; Ceruti, R; Cribioli, S; Giussani, U; Golay, J; Introna, M; Losa, M; Marchesi, F; Patton, V; Pesenti, E; Pezzoni, A; Rambaldi, A; Texido, G; Valsasina, B1
Negoro, E; Shigemi, H; Ueda, T; Uzui, K; Yamauchi, T; Yoshida, A1
Ando, K; Bay, JO; Giagounidis, A; Gröpper, S; Jabbour, EJ; Kantarjian, HM; Martinelli, G; Owen, K; Papayannidis, C; Pike, L; Quintás-Cardama, A; Schmitt, N; Stockman, PK; Wei, A1
Garcia-Manero, G; Jabbour, EJ; Kantarjian, HM; Oliver, SD; Owen, K; Ribrag, V; Rousselot, P; Sekeres, MA; Stockman, PK1
Fenaux, P; Galluzzi, L; Kepp, O; Kroemer, G; Lainey, E; Micol, JB; Sukkurwala, AQ; Wolfromm, A1
Chen, JJ; Fang, ZG; Lin, DJ; Liu, LL; Liu, Q; Long, ZJ; Wang, LX; Wang, SW; Xu, DF; Yan, M; Zheng, FM1
Fu, R; Yang, R; Zhang, L1
Hu, B; Mohty, M; Savani, BN; Vikas, P1
Amrein, PC; Berchuck, J; Deangelo, DJ; Galinsky, I; Golub, T; Neuberg, D; Sirulnik, LA; Stegmaier, K; Stone, RM; Wadleigh, M1
Hébert, J; Humphries, RK; Jin, J; Kirschner, J; Krosl, J; Lehnertz, B; Liu, F; Miller, M; Pabst, C; Rossi, FM; Rosten, P; Sauvageau, G; Su, L; Underhill, TM; Yi, L; Yung, E; Zhang, R1
Fulp, WJ; Komrokji, RS; Lancet, JE; List, AF; Padron, E; Rodriguez, Y; Tinsley, S; Yu, D1
Erlichman, C; Flynn, PJ; Juckett, MB; Jumonville, A; LaPlant, B; Mattison, R; Moreno-Aspitia, A1
Adès, L; Beyne-Rauzy, O; Boehrer, S; Chermat, F; Delaunay, J; Fenaux, P; Hunault, M; Jourdan, E; Kroemer, G; Prebet, T; Raffoux, E; Sebert, M; Seegers, V; Thepot, S; Wattel, E1
Amin, C; Cangany, M; Cripe, LD; Czader, M; Konig, H; Sayar, H1
Erba, HP1
Gelston, E; Liu, A; Liu, Q; Wang, B; Wang, H; Wu, X; Xu, J; Xu, L; Zeng, Y; Zhou, W; Zou, Z1
Chakravarti, B; Chattopadhyay, N; Datta, D; Dogra, S; Gurjar, A; Kumar, H; Kushwaha, S; Rao, G; Sanyal, S; Singh, AK; Tripathi, AK; Trivedi, AK; Vishwakarma, AL; Yadav, M; Yadav, PN1
Arnold, R; Bal, G; Bozzetti, C; Fransecky, L; Hemmati, P; le Coutre, P; Richter, U; Riess, H; Schulz, CO; Türkmen, S1
Chang, CW; Chang, YI; Chen, CH; Chen, CP; Chen, CT; Chen, PY; Coumar, MS; Hsieh, HP; Hsu, JT; Hsu, YC; Huang, CL; Ke, YY; Kuo, CC; Kuo, FM; Kuo, PC; Li, AS; Lin, WH; Shiao, HY; Shih, C; Song, JS; Wang, SY; Wang, WC; Wu, MH; Yeh, TK; Yen, KJ1
Ashton, S; Barry, ST; Caddy, J; Curtis, NJ; Derbyshire, N; Floc'h, N; Harris, E; Hattersley, M; Jacobs, VN; Maratea, K; Odedra, R; Pease, EJ; Pilling, JE; Taylor, P; Trueman, D; Wen, S1
Adès, L; Boehrer, S; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Kroemer, G; Tailler, M; Tajeddine, N1
Aleskog, A; Danielsson, K; Eriksson, A; Grundmark, B; Henriksson, R; Höglund, M; Larsson, R; Lindhagen, E; Nygren, P; Wickström, M1
Altavilla, G; Arrigo, C; Pitini, V1
Bonnet, D; Cavenagh, J; Crafter, C; Fitzgibbon, J; Joel, S; Lister, AT; Odedra, R; Oke, A; Pearce, D; Wilkinson, RW1
Heinrich, MC; Kampa, KM; Schittenhelm, MM; Yee, KW1
Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP1
Berdel, WE; Collins, B; Ehninger, G; Fiedler, W; Heuser, M; Jürgensmeier, JM; Mesters, R; Puchalski, TA; Robertson, JD; Serve, H; Zirrgiebel, U1
Downing, JR1
Berchuck, JE; Carr, SA; Carroll, M; Clauser, K; Davis, TN; DeAngelo, DJ; Galinsky, I; Golub, TR; Hahn, CK; Hahn, WC; Kakoza, RM; Kung, AL; Root, DE; Ross, KN; Ross, L; Schinzel, AC; Silver, SJ; Stegmaier, K; Stone, RM1
Ikezoe, T; Nishioka, C; Yang, J; Yokoyama, A1
Freidlin, B; Korn, EL; McShane, LM1
Grundy, M; Pallis, M; Richardson, J; Russell, N; Seedhouse, C; Shang, S1
Beausoleil, S; Druker, BJ; Gu, TL; Gygi, SP; Heinrich, MC; Kornhauser, J; Loriaux, M; MacNeill, J; Nardone, J; Polakiewicz, RD; Ren, J; Rush, J; Tucker, M; Villén, J; Wang, Y1
Ando, K; Asou, H; Fujisawa, S; Hotta, T; Kihara, R; Miyawaki, S; Sakura, T; Tobinai, K; Tsuboi, K; Uike, N; Watanabe, T; Yamauchi, T; Yokozawa, T1
Grundy, M; Pallis, M; Russell, NH; Seedhouse, C1
Adès, L; Boehrer, S; Bouteloup, C; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Harper, F; Kroemer, G; Lainey, E; Pierron, G; Sébert, M; Tailler, M; Thépot, S1
Amadori, S; Berman, E; Cahn, JY; Faderl, S; Goudie, A; Ifrah, N; Jabbour, E; Jongen-Lavrencic, M; Kantarjian, H; Löwenberg, B; Martinelli, G; Muus, P; Ossenkoppele, G; Rigaudeau, S; Rousselot, P; Sonneveld, P; Stockman, P1
Daub, H; Schreiber, TB; Weber, C1
Atrash, B; Avery, S; Bavetsias, V; Blagg, J; de Haven Brandon, A; Eccles, SA; Faisal, A; Gonzalez de Castro, D; Linardopoulos, S; Mair, D; Mirabella, F; Moore, AS; Pearson, AD; Raynaud, FI; Sun, C; Swansbury, J; Valenti, M; Workman, P1
Cao, ZX; Feng, S; Ji, P; Li, WW; Liu, JJ; Ma, S; Sun, QZ; Wang, LJ; Wang, XY; Wang, ZR; Wei, YQ; Xu, Y; Yan, HX; Yang, J; Yang, LL; Yang, SY; Zhang, CH; Zheng, RL; Zhong, L1
D'Souza, R; Davies, M; Dennis, M; Oliver, S; Pike, L; Stockman, P1
Calvert, VS; Caron, HN; de Haas, V; Den Boer, ML; Evans, WE; Exalto, C; Hansen, BR; Hartsink-Segers, SA; Hedtjärn, M; Koch, T; Luijendijk, MW; Petricoin, EF; Pieters, R; Reinhardt, D; Zwaan, CM1
Bouteloup, C; De Botton, S; Enot, D; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Marie, N; Micol, JB; Scoazec, M; Wolfromm, A1
Bouteloup, C; De Botton, S; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Scoazec, M; Sébert, M; Thépot, S1
Abe, K; Amaral, SM; Apatira, M; Boulton, CL; Curley, DP; Duclos, N; Giese, NA; Gilliland, DG; Hollenbach, S; Kelly, LM; Li, J; Lokker, NA; Neuberg, D; Pandey, A; Scarborough, RM; Sullivan, CM; Williams, I; Yu, JC1
Corbin, AS; Deininger, MW; Druker, BJ; Griswold, IJ; Heinrich, MC; La Rosée, P; Reimer, CL; Yee, KW1
Deininger, MW; Druker, BJ; Heinrich, MC; Stoffregen, EP; Walters, DK1
Corsello, SM; Deangelo, DJ; Golub, TR; Ross, KN; Stegmaier, K; Wong, JS1
Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE1
Barbui, T; Finazzi, G1
Bassères, DS; Bohlander, SK; Davis, RJ; Dayaram, T; Delmotte, MH; Giese, NA; Gilliland, DG; Hiddemann, W; Lokker, N; Radomska, HS; Schnittger, S; Small, D; Sternberg, DW; Tenen, DG; Yamamoto, Y; Zhang, P; Zheng, R1
Billottet, C; Gale, RE; Grandage, VL; Khwaja, A; Quattropani, A; Rommel, C; Vanhaesebroeck, B1
Caligiuri, MA; Cooper, MR; Curtin, PT; DeAngelo, DJ; Druker, BJ; Heaney, ML; Heinrich, MC; Holford, N; Karol, MD; Klisovic, RB; Lecerf, JM; Nimer, SD; Paquette, RL; Sheng, S; Stone, RM1
Bandobashi, K; Ikezoe, T; Koeffler, HP; Komatsu, N; Kuwayama, Y; Nishioka, C; Taguchi, H; Taniguchi, A; Tasaka, T; Togitani, K; Yang, J1
Chan, G; Pilichowska, M1
Adès, L; Boehrer, S; Braun, T; de Botton, S; Fabre, C; Fenaux, P; Galluzzi, L; Gardin, C; Grosjean, J; Kroemer, G; Le Roux, G; Martin, A1
Cheng, Y; Paz, K1
Ehninger, G; Illmer, T1
Duan, R; Grandis, JR; Johnson, DE; Jones, JE; Miranda, MB; Redner, RL; Thomas, SM1
Gary Gilliland, D; Tam, WF1
Burnett, A; Mills, K; Pepper, C; Walsby, E; Walsh, V1
Kobayashi, H; Miyachi, H; Takemura, Y1
Abels, J; Ermens, AA; Lindemans, J1
Grignani, F; Martelli, M; Tonato, M1
Bertino, JR; Capizzi, RL; Cashmore, AR; Johns, DG; Nahas, A1

Reviews

7 review(s) available for quinazolines and Leukemia, Myeloid, Acute

ArticleYear
[Treatment of essential thrombocythemia].
    Medicina clinica, 2013, Sep-21, Volume: 141, Issue:6

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progression; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Intraoperative Complications; Janus Kinase 2; Leukemia, Myeloid, Acute; Life Expectancy; Male; Middle Aged; Mutation, Missense; Platelet Aggregation Inhibitors; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombophilia

2013
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.
    British journal of haematology, 2013, Volume: 163, Issue:3

    Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression; GPI-Linked Proteins; Hemorrhage; Humans; Hydroxyurea; Incidence; Infant; Isoantigens; Janus Kinase 2; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Point Mutation; Primary Myelofibrosis; Quinazolines; Receptors, Cell Surface; Risk Assessment; Symptom Assessment; Thrombocythemia, Essential; Thrombophilia

2013
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
    Expert review of hematology, 2014, Volume: 7, Issue:2

    Topics: Carbazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous

2014
Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
    Leukemia research, 2015, Volume: 39, Issue:2

    Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Critical Care; Cytarabine; Decitabine; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Organophosphates; Quinazolines; Quinolones

2015
Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.
    IDrugs : the investigational drugs journal, 2008, Volume: 11, Issue:1

    Topics: Administration, Oral; Animals; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Piperazines; Quinazolines

2008
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
    Clinical lymphoma & myeloma, 2007, Volume: 8 Suppl 1

    Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib

2007
Can FLT3 inhibitors overcome resistance in AML?
    Best practice & research. Clinical haematology, 2008, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Piperazines; Quinazolines; Staurosporine

2008

Trials

14 trial(s) available for quinazolines and Leukemia, Myeloid, Acute

ArticleYear
Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study.
    Leukemia research, 2018, Volume: 74

    Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Quinazolines; Thrombocythemia, Essential

2018
The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.
    PloS one, 2013, Volume: 8, Issue:3

    Topics: Adult; Animals; CD56 Antigen; Cell Cycle Proteins; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Experimental; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2013
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
    Cancer, 2013, Jul-15, Volume: 119, Issue:14

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Cytarabine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Neutropenia; Organophosphates; Protein Serine-Threonine Kinases; Quinazolines; Stomatitis; Treatment Outcome

2013
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Organophosphates; Quinazolines; Treatment Outcome

2013
A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.
    Leukemia research, 2014, Volume: 38, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinazolines; Treatment Failure

2014
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.
    American journal of hematology, 2014, Volume: 89, Issue:8

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Azacitidine; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure

2014
A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Risk Factors; Salvage Therapy; Survival Rate

2015
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.
    Leukemia research, 2014, Volume: 38, Issue:12

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Remission Induction

2014
An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.
    Leukemia research, 2010, Volume: 34, Issue:2

    Topics: Aged; Aged, 80 and over; Diarrhea; Fatigue; Female; Humans; Hypertension; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects; Proto-Oncogene Proteins c-kit; Quinazolines; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2

2010
A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.
    Leukemia research, 2011, Volume: 35, Issue:10

    Topics: Adult; Antineoplastic Agents; Asian People; Aurora Kinase B; Aurora Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Neutropenia; Organophosphates; Protein Serine-Threonine Kinases; Quinazolines; Treatment Outcome

2011
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
    Blood, 2011, Dec-01, Volume: 118, Issue:23

    Topics: Aged; Aged, 80 and over; Aurora Kinase B; Aurora Kinases; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Organophosphates; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Recurrence; Severity of Illness Index

2011
Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:3

    Topics: Adult; Aged; Aurora Kinase B; Aurora Kinases; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Organophosphates; Prodrugs; Protein Serine-Threonine Kinases; Quinazolines; Remission Induction; Time Factors; Treatment Outcome

2012
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential; Thrombosis

2005
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
    Blood, 2006, Dec-01, Volume: 108, Issue:12

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Marrow; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Quinazolines; Receptors, Platelet-Derived Growth Factor

2006

Other Studies

56 other study(ies) available for quinazolines and Leukemia, Myeloid, Acute

ArticleYear
Synthesis and biological evaluation of novel 5,6-dihydrobenzo[h]quinazoline derivatives as FLT3 inhibitors.
    Chemical biology & drug design, 2022, Volume: 99, Issue:4

    Topics: Apoptosis; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Protein Kinase Inhibitors; Quinazolines

2022
Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells.
    The Journal of pharmacy and pharmacology, 2023, Mar-12, Volume: 75, Issue:3

    Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP1A1; Drug-Related Side Effects and Adverse Reactions; Gefitinib; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Quinazolines; RNA, Messenger

2023
Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.
    Nature chemical biology, 2021, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Aurora Kinase A; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Drug Design; Drug Discovery; Gene Expression Regulation, Leukemic; Humans; Ikaros Transcription Factor; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Myeloid Progenitor Cells; Piperazines; Primary Cell Culture; Proteolysis; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Structure-Activity Relationship; Transcriptome; Triazoles

2021
DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia.
    Scientific reports, 2021, 06-09, Volume: 11, Issue:1

    Topics: Animals; Apoptosis; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Repair; DNA-Activated Protein Kinase; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2021
Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2021, Volume: 35, Issue:7

    Topics: Antigens, Surface; Cell Cycle Proteins; Cytarabine; Fatty Acids; HL-60 Cells; Humans; Immunity; Jurkat Cells; Leukemia, Myeloid, Acute; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteome; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Quinazolines

2021
Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
    PloS one, 2017, Volume: 12, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Line, Tumor; Female; fms-Like Tyrosine Kinase 3; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fes; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Tandem Repeat Sequences

2017
Selective Inhibition of the Myeloid Src-Family Kinase Fgr Potently Suppresses AML Cell Growth in Vitro and in Vivo.
    ACS chemical biology, 2018, 06-15, Volume: 13, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Female; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-hck; Quinazolines; src-Family Kinases; Xenograft Model Antitumor Assays

2018
Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells.
    Biochemical and biophysical research communications, 2018, 09-10, Volume: 503, Issue:3

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Phosphorylation; Protein Isoforms; Protein Kinase C-alpha; Proto-Oncogene Proteins c-pim-1; Pyrroles; Quinazolines; Serine

2018
Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.
    Molecular cancer therapeutics, 2018, Volume: 17, Issue:12

    Topics: Animals; Apoptosis; Aurora Kinases; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Female; G1 Phase; Humans; Leukemia, Myeloid, Acute; Megakaryocytes; Mice; Mitosis; Organophosphates; Phthalazines; Polyploidy; Protein Isoforms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2018
Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 117

    Topics: Aurora Kinase A; Aurora Kinase B; Azepines; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Humans; Leukemia, Myeloid, Acute; Organophosphates; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Time Factors; Translocation, Genetic; Tumor Stem Cell Assay

2019
Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.
    Cancer science, 2013, Volume: 104, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Cell Division; Cell Line, Tumor; Cytarabine; Histones; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Organophosphates; Phosphorylation; Quinazolines; U937 Cells

2013
EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells.
    Cell cycle (Georgetown, Tex.), 2013, Sep-15, Volume: 12, Issue:18

    Topics: Antigens, CD34; CD11b Antigen; Cell Cycle Checkpoints; Cell Differentiation; Cholecalciferol; ErbB Receptors; Erlotinib Hydrochloride; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 14; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Tretinoin; Tumor Cells, Cultured

2013
Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism.
    Molecular cancer research : MCR, 2013, Volume: 11, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Aurora Kinases; Benzamides; Cell Line, Tumor; Deoxyglucose; Gene Expression Regulation, Neoplastic; Glucose; Glycolysis; HL-60 Cells; Humans; Indoles; Lactic Acid; Leukemia, Myeloid, Acute; Piperazines; Polyploidy; Purines; Quinazolines; Sequestosome-1 Protein; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; U937 Cells

2013
The methyltransferase G9a regulates HoxA9-dependent transcription in AML.
    Genes & development, 2014, Feb-15, Volume: 28, Issue:4

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; HEK293 Cells; Hematopoietic Stem Cells; Histone-Lysine N-Methyltransferase; Homeodomain Proteins; Humans; Leukemia, Myeloid, Acute; Mice, Inbred C57BL; Quinazolines

2014
Pilot study of erlotinib in patients with acute myeloid leukemia.
    Leukemia research, 2015, Volume: 39, Issue:2

    Topics: Aged; Aged, 80 and over; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Pilot Projects; Protein Kinase Inhibitors; Quinazolines

2015
Inhibition of Bcl-xL overcomes polyploidy resistance and leads to apoptotic cell death in acute myeloid leukemia cells.
    Oncotarget, 2015, Aug-28, Volume: 6, Issue:25

    Topics: Aniline Compounds; Apoptosis; bcl-X Protein; Benzamides; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Indoles; Leukemia, Myeloid, Acute; Mitosis; Oxindoles; Phosphorylation; Polyploidy; Quinazolines; RNA, Small Interfering; Sulfonamides; U937 Cells; Vinblastine

2015
Epidermal growth factor receptor inhibitor cancer drug gefitinib modulates cell growth and differentiation of acute myeloid leukemia cells via histamine receptors.
    Biochimica et biophysica acta, 2016, Volume: 1860, Issue:10

    Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclic AMP; ErbB Receptors; Gefitinib; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H2; Receptors, Histamine H4

2016
A Rare Case of Acute Myeloid Leukemia with a t(2;3) Chromosomal Translocation Characterized by Thrombophilia and Chemoresistance.
    Journal of clinical and experimental hematopathology : JCEH, 2016, Volume: 56, Issue:1

    Topics: Blood Platelets; DNA-Binding Proteins; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Proto-Oncogenes; Quinazolines; Stem Cell Transplantation; Thrombophilia; Transcription Factors; Translocation, Genetic

2016
Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation.
    Oncotarget, 2016, Dec-27, Volume: 7, Issue:52

    Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Cell Line, Tumor; Drug Design; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship

2016
Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase B; Bone Marrow; Cell Line, Tumor; Cytarabine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Nanoparticles; Organophosphates; Polyploidy; Protein Kinase Inhibitors; Quinazolines; Rats; Tumor Burden; Xenograft Model Antitumor Assays

2017
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison.
    Biochemical pharmacology, 2008, Dec-01, Volume: 76, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines

2008
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia.
    European journal of haematology, 2008, Volume: 81, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Caspase 3; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Humans; Immunochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinazolines; Tumor Cells, Cultured

2008
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-20, Volume: 26, Issue:21

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Quinazolines; Smoking; Tomography, X-Ray Computed

2008
AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.
    Cancer research, 2009, May-15, Volume: 69, Issue:10

    Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Aurora Kinase B; Aurora Kinases; Cell Division; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Hematopoietic Stem Cells; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Organophosphates; Protein Serine-Threonine Kinases; Quinazolines; U937 Cells

2009
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
    Cell cycle (Georgetown, Tex.), 2009, Aug-15, Volume: 8, Issue:16

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Proliferation; Cytarabine; Daunorubicin; Drug Synergism; Flow Cytometry; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Piperazines; Quinazolines

2009
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
    Blood, 2009, Oct-01, Volume: 114, Issue:14

    Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays

2009
Can treating the SYK cell cure leukemia?
    Cancer cell, 2009, Oct-06, Volume: 16, Issue:4

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Regulation, Leukemic; Genomics; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; Syk Kinase; Time Factors; Tyrosine

2009
Proteomic and genetic approaches identify Syk as an AML target.
    Cancer cell, 2009, Oct-06, Volume: 16, Issue:4

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genomics; HL-60 Cells; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; RNA Interference; Syk Kinase; Tandem Mass Spectrometry; Time Factors; Tumor Cells, Cultured; Tyrosine; U937 Cells; Xenograft Model Antitumor Assays

2009
p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells.
    International journal of hematology, 2010, Volume: 91, Issue:1

    Topics: Apoptosis; Aurora Kinase B; Aurora Kinases; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53; Up-Regulation

2010
Randomized clinical trials with biomarkers: design issues.
    Journal of the National Cancer Institute, 2010, Feb-03, Volume: 102, Issue:3

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Endonucleases; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Staurosporine

2010
The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Aurora Kinase B; Aurora Kinases; Cell Survival; Drug Delivery Systems; Drug Evaluation, Preclinical; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Histones; Humans; Leukemia, Myeloid, Acute; Mutagenesis, Insertional; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Tandem Repeat Sequences; Tumor Cells, Cultured; U937 Cells

2010
Survey of activated FLT3 signaling in leukemia.
    PloS one, 2011, Apr-28, Volume: 6, Issue:4

    Topics: Bone Marrow Cells; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Phosphoamino Acids; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinazolines; Signal Transduction

2011
P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
    BMC cancer, 2011, Jun-16, Volume: 11

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Aurora Kinase B; Aurora Kinases; Cell Line, Tumor; Daunorubicin; Drug Resistance, Neoplasm; Female; Histones; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Organophosphates; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Quinazolines

2011
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.
    Cell cycle (Georgetown, Tex.), 2011, Sep-15, Volume: 10, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Enzyme Activation; Erlotinib Hydrochloride; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Microscopy, Electron; Microscopy, Fluorescence; Microtubule-Associated Proteins; Phosphorylation; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; src-Family Kinases; Stilbenes; TOR Serine-Threonine Kinases

2011
Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.
    Journal of proteomics, 2012, Feb-02, Volume: 75, Issue:4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mass Spectrometry; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction

2012
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Leukemia, 2012, Volume: 26, Issue:7

    Topics: Animals; Apoptosis; Aurora Kinases; Benzenesulfonates; Benzothiazoles; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Quinazolines; Sorafenib; Tandem Repeat Sequences; Tumor Cells, Cultured

2012
Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.
    Journal of medicinal chemistry, 2012, Apr-26, Volume: 55, Issue:8

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Phenylurea Compounds; Quinazolines; Structure-Activity Relationship; Thiadiazoles; Xenograft Model Antitumor Assays

2012
Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.
    Leukemia, 2013, Volume: 27, Issue:3

    Topics: Adult; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Biomarkers, Tumor; Blotting, Western; Bone Marrow; Case-Control Studies; Cell Proliferation; Child; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Oligonucleotide Array Sequence Analysis; Oligonucleotides; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured

2013
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.
    Oncogene, 2013, Sep-12, Volume: 32, Issue:37

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; DNA Damage; Drug Synergism; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines

2013
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
    Cell cycle (Georgetown, Tex.), 2012, Nov-01, Volume: 11, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Down-Regulation; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Quinazolines

2012
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
    Cancer cell, 2002, Volume: 1, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Marrow Transplantation; Enzyme Inhibitors; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Immunoblotting; Interleukin-3; Leukemia, Myeloid, Acute; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Cell Surface; Receptors, Platelet-Derived Growth Factor; Tandem Repeat Sequences; Transfection; Tumor Cells, Cultured

2002
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
    Blood, 2004, Dec-01, Volume: 104, Issue:12

    Topics: Animals; Cell Line; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Mice; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridones; Pyrimidines; Quinazolines

2004
RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.
    Blood, 2005, Apr-01, Volume: 105, Issue:7

    Topics: Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Transfection

2005
Gefitinib induces myeloid differentiation of acute myeloid leukemia.
    Blood, 2005, Oct-15, Volume: 106, Issue:8

    Topics: Biomarkers, Tumor; Cell Differentiation; Cell Survival; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Leukemia, Myeloid, Acute; Quinazolines; Tumor Cells, Cultured

2005
When and how to treat essential thrombocythemia.
    The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1

    Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis

2005
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
    The Journal of experimental medicine, 2006, Feb-20, Volume: 203, Issue:2

    Topics: Aged; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Line; Enzyme Activation; Female; fms-Like Tyrosine Kinase 3; Granulocytes; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; MAP Kinase Kinase 1; Myeloid Cells; Phosphorylation; Piperazines; Point Mutation; Quinazolines; Serine; Tumor Cells, Cultured; U937 Cells

2006
A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16.
    Oncogene, 2006, Oct-26, Volume: 25, Issue:50

    Topics: Adenine; Apoptosis; Cell Proliferation; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Enzyme Activation; Etoposide; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Isoforms; Quinazolines

2006
A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:6

    Topics: Apoptosis; Aurora Kinase A; Aurora Kinases; Base Sequence; Benzamides; Cell Division; DNA Primers; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Protein Serine-Threonine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured

2007
Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell lung cancer.
    Blood, 2007, Aug-01, Volume: 110, Issue:3

    Topics: Aged; Carcinoma, Small Cell; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines; Remission Induction

2007
Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study.
    Blood, 2008, Feb-15, Volume: 111, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Reference Values

2008
Gefitinib potentiates myeloid cell differentiation by ATRA.
    Leukemia, 2008, Volume: 22, Issue:8

    Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Drug Synergism; Gefitinib; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Quinazolines; Tretinoin

2008
Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
    Haematologica, 2008, Volume: 93, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Aurora Kinases; Benzamides; Blast Crisis; Cell Proliferation; Enzyme Inhibitors; Histones; Humans; Leukemia, Myeloid, Acute; Organophosphates; Phosphorylation; Ploidies; Polyploidy; Protein Serine-Threonine Kinases; Quinazolines; Tumor Cells, Cultured

2008
Raltitrexed, a novel folate-based thymidylate synthase inhibitor, for the treatment of acute leukemia: is this drug active against acute myelogenous leukemia?
    International journal of hematology, 2000, Volume: 72, Issue:1

    Topics: Antimetabolites, Antineoplastic; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Leukemia, Myeloid, Acute; Molecular Structure; Quinazolines; Thiophenes; Thymidylate Synthase

2000
Moderate antiproliferative effect of the antifolate CB3717 in the BN myeloid leukaemia model.
    British journal of cancer, 1988, Volume: 57, Issue:4

    Topics: Animals; Antineoplastic Agents; Deoxyuridine; DNA; Fluorouracil; Folic Acid; Folic Acid Antagonists; Leukemia, Myeloid, Acute; Quinazolines; Rats; Thymidine Monophosphate; Thymidylate Synthase

1988
[Antimetabolites in the therapy of acute human leukoses. Mechanism of action and conditioning factors in the cellular response to drugs. I].
    La Clinica terapeutica, 1974, Apr-15, Volume: 69, Issue:1

    Topics: Aminopterin; Antimetabolites; Azaguanine; Cytarabine; DNA, Neoplasm; Humans; Immunity, Cellular; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Mercaptopurine; Purines; Quinazolines; RNA, Neoplasm

1974
Quinazoline antifolates as inhibitors of dihydrofolate reductase from human leukemia cells.
    Biochemical pharmacology, 1970, Volume: 19, Issue:4

    Topics: Adult; Aged; Animals; Biological Transport; Cell Line; Chemical Precipitation; Chromatography; Chromatography, Gel; Deoxyuridine; DNA, Neoplasm; Female; Folic Acid Antagonists; Humans; Hydroxyapatites; Leukemia L1210; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Methotrexate; Mice; Quaternary Ammonium Compounds; Quinazolines; Spectrophotometry; Sulfates; Tetrahydrofolate Dehydrogenase; Tritium; Ultraviolet Rays

1970